Company: BIAF
Filing Date: 2025-05-02
Form Type: S-1
Source: 0001641172-25-008170
Chunk: 13

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-05-02
Form: S-1
Chunk 13
---
 accounting standards. As a result of the accounting standards election, we will not be subject to the same implementation timing for new or revised accounting standards as other public companies that are not EGCs which may make comparison of our financials to those of other public companies more difficult.

Summary of Risk Factors

Like any emerging growth company, we face significant risk factors that may impede our plans for successful commercialization of our diagnostic and therapeutic products. These risks are discussed in detail under the “Risk Factors” discussion beginning on page 7 of this prospectus.

The following summarizes the principal factors that make an investment in our Company speculative or risky, all of which are more fully described in the section below titled “Risk Factors.” This summary should be read in conjunction with the section below titled “Risk Factors” and should not be relied upon as an exhaustive summary of the material risks facing our business. The following factors could result in harm to our business, reputation, revenue, financial results, and prospects, among other impacts:

Risks Related to Our Financial Position

| ● | Our                                                                                          
 business plan relies upon our ability to obtain additional sources of capital and financing. |

| ● | We                                                                                            
 must raise additional capital to fund our operations in order to continue as a going concern. |

| ● | Our                                                                                         
 limited operating history makes it difficult to evaluate our business and future prospects. |

| ● | We                                                                                            
 are unable to precisely estimate when we will begin to generate significant profit from PPLS. |

| ● | We                                              
 have limited experience operating a laboratory. |

| 2 |

Risks Related to this Offering

| ● | Our                                                                                        
 management will have broad discretion over the use of the net proceeds from this offering. |

| ● | You                                                                                               
 may experience dilution in the net tangible book value per share of the Common Stock issued       
 in this offering or that may be issued upon the exercise of any warrants issued in this offering. |

| ● | Future                                                                                       
 issuances of our Common Stock or rights to purchase Common Stock, could result in additional 
 dilution of the percentage ownership of our stockholders and could cause our stock price     
 to fall.                                                                                     |

| ● | If                                                                                        
 we issue additional securities it could adversely affect the rights of the holders of our 
 Common Stock.                                                                             |

| ● | We                                                                                        
 may not raise the amount of capital we believe is required for our business plans in this 
 offering.                                                                                 |

| ● | Investors                                                                                
 in this offering will not receive a refund in